Wendy Lee, MD
Ophthalmic Plastic and Reconstructive Surgery · Miami, FLNPI 1306979620
Payments from drug & device makers
Across 582 payments — averaging $1058.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$293K
- Galderma Laboratories, L.p.$130K
- Mallinckrodt Enterprises LLC$75K
- Amgen$34K
- Mallinckrodt Hospital Products Inc.$24K
- Argenx US, Inc.$20K
- plus $41K from 24 others
What the payments were for
- Consulting fees$184,04430%
- Speaking & faculty fees$344,98756%
- Travel & lodging$65,17611%
- Food & beverage$21,5513%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 289 | $292,785 |
| Galderma Laboratories, L.p. | 103 | $130,018 |
| Mallinckrodt Enterprises LLC | 49 | $74,948 |
| Amgen(2 entities) | 47 | $33,676 |
| Mallinckrodt Hospital Products Inc. | 14 | $23,640 |
| Argenx US, Inc. | 14 | $20,124 |
| Solta Medical, A Division Of Bausch Health US, LLC | 4 | $12,180 |
| Osmotica Pharmaceutical Corp. | 3 | $9,249 |
| Oyster Point Pharma, Inc. | 6 | $5,855 |
| Tarsus Pharmaceuticals, Inc. | 4 | $5,328 |
| Bausch & Lomb Americas Inc. | 5 | $4,557 |
| Sun Pharmaceutical Industries Inc. | 13 | $848 |
| Revance Therapeutics, Inc. | 5 | $655 |
| Ivantis, Inc | 4 | $604 |
| Carl Zeiss Meditec USA, Inc. | 2 | $252 |
| Merz North America, Inc. | 2 | $193 |
| Kala Pharmaceuticals, Inc. | 1 | $139 |
| Alcon | 2 | $133 |
| Astellas Pharma US Inc | 1 | $108 |
| Novartis | 1 | $99 |
| Endo Pharmaceuticals Inc. | 2 | $93 |
| Sight Sciences, Inc. | 2 | $67 |
| Biotissue Holdings Inc. | 2 | $50 |
| Johnson & Johnson | 1 | $43 |
| Eyevance Pharmaceuticals LLC | 1 | $32 |
| Eyepoint US, Inc. | 1 | $30 |
| Caris MPI, Inc. | 1 | $24 |
| Medtronic | 1 | $19 |
| Katalyst Surgical, LLC | 1 | $15 |
| Poriferous LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$127,747
- ACTHAR$97,961
- BOTOX COSMETIC$62,974
- TEPEZZA$31,337
- VYVGART HYTRULO$11,942
- VYVGART$7,800
- TYRVAYA$3,706
- XDEMVY$1,195
- DAXXIFY$647
- Hydrus$467
- CEQUA$390
- DYSPORT$286
- XEOMIN$175
- VUITY$148
- INVELTYS$139
- EYSUVIS$139
- Hydrus Microstent$137
- IOLMaster 700$113
How this compares
$615,780 in reported general payments places this provider in the 90th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.
See all ophthalmic plastic and reconstructive surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 11 | $941,716 |
| ErythromycinErythromycin Base | 61 | $634 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 19 | $211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $23,640 | $941,71611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.
Other ophthalmic plastic and reconstructive surgery in Miami
- Sara WesterMiami$1.1M
- Jennifer MurdockMiami$316K
- Ana VictoriaMiami$130K
- Catherine ChoiMiami$596
- Myron TanenbaumMiami$551
- William EvansMiami$412
- Michelle LattingMiami$352
- John FezzaVenice$3.9M
- Keshini ParbhuWindermere$102K
- Robert ApplebaumLakeland$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.